Protein Binding and Biotransformation Dynamics
Will My Compound Bind to Albumin?
In the realm of early stage drug candidate screening, understanding exactly how a molecule behaves in the human body is paramount. Relying on advanced drug discovery ADME tools, Spirographic AI allows researchers to look beyond simple affinity scores to map the precise metabolic fate of their compounds.
Albumin Binding Site Predictions
Dual Binding Analysis
When researchers ask, “will my compound bind to albumin,” a simple yes or no is no longer sufficient. The Spirographic AI system now includes dual binding prediction capabilities, addressing the critical clinical gap of multi-site binding drugs. Forty-two drugs (6.6% of the validation dataset) are known dual binders that occupy multiple albumin sites simultaneously. The enhanced system successfully identifies these dual binders with >95% confidence, providing clinicians with displacement risk assessment and quantitative drug-drug interaction screening capabilities unavailable in any competing platform. This enhancement empowers researchers to anticipate complex pharmacokinetic interactions early in the development pipeline.
Cytochrome P450: 99.4% Accuracy Across 8 Isoforms
The Spirographic AI CYP450 Isoform Screening System delivers world-class accuracy with 99.4% precision across eight major cytochrome P450 enzymes. It successfully allows developers to identify CYP450 isoform metabolism substrates for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 from molecular structure alone. With 100% specificity and zero false positives across 784 predictions, the system provides pharmaceutical companies with unparalleled confidence in drug-drug interaction screening, personalized dosing strategies, and regulatory submissions. Our comprehensive validation on 98 drugs demonstrates perfect negative control recognition for non-CYP metabolized compounds, ensuring accurate identification of alternative clearance pathways. This industry-leading performance enables precise clinical decision support, reduces late-stage development failures, and accelerates drug approval timelines through reliable ADME profiling.
CYP450 Metabolite Prediction Engine
50.2% Exact Matches
Validated against 213 experimentally confirmed metabolites, Spirographic AI’s CYP450 metabolite prediction engine achieves a 50.2% exact SMILES match and 62.9% structural similarity (Tanimoto ≥ 0.7) — placing it in the range of leading commercial metabolite prediction platforms. By leveraging sophisticated medicinal chemistry SMILES analysis, an exact match identifies the precise metabolic product, while structural similarity captures chemically meaningful predictions where the transformation site is correct but stereochemistry or minor substitution differs. Together, these metrics reflect a system that correctly characterizes the majority of what the liver actually makes from a candidate compound — providing the critical early signal for metabolic liability, reactive intermediate formation, and toxicity risk before any human exposure occurs.